We are live on ! Find out more
FNCH

Finch Therapeutics Group, Inc. Common Stock
FNCH

Delisted

FNCH was delisted on the 24th of May, 2024.

Back to rankings

43 hedge funds and large institutions have $16.8M invested in Finch Therapeutics Group, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

7% less funds holding

Funds holding: 46 → 43 (-3)

18% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 11

40% less capital invested

Capital invested by funds: $28M → $16.8M (-$11.2M)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $2K

Holders
43
Holders Change
-3
Holders Change %
-6.52%
% of All Funds
0.74%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
4
Increased
9
Reduced
11
Closed
7
Calls
–
Puts
$2K
Net Calls
-$2K
Net Calls Change
+$1K

Top Buyers

Rank Fund Capital Flow
1
SW
SVB Wealth
Massachusetts
+$587K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$247K
3
Millennium Management
Millennium Management
New York
+$69.2K
4
VF
Virtu Financial
New York
+$35.2K
5
BCM
Bridgeway Capital Management
Texas
+$26.1K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$216K
2
E
Ergoteles
New York
-$104K
3
Citadel Advisors
Citadel Advisors
Florida
-$70K
4
Morgan Stanley
Morgan Stanley
New York
-$62.1K
5
BFM
Boothbay Fund Management
New York
-$40.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$32K -$32K -460 -42%
AA
27
Ancora Advisors
Ohio
$27K -$36.5K -525 -50%
VF
28
Virtu Financial
New York
$25K +$35.2K +506 New
HighTower Advisors
29
HighTower Advisors
Illinois
$22K -$16.1K -232 -33%
WP
30
WealthSource Partners
California
$19K – – –
Dimensional Fund Advisors
31
Dimensional Fund Advisors
Texas
$17K +$23.3K +335 New
Bank of America
32
Bank of America
North Carolina
$14K +$4.17K +60 +28%
SPIA
33
Steward Partners Investment Advisory
New York
$4K – – –
Simplex Trading
34
Simplex Trading
Illinois
$2K -$348 -5 -9%
Osaic Holdings
35
Osaic Holdings
Arizona
$2K +$278 +4 +13%
Morgan Stanley
36
Morgan Stanley
New York
$1K -$62.1K -893 -97%
Northwestern Mutual Wealth Management
37
Northwestern Mutual Wealth Management
Wisconsin
$1K – – –
E
38
Ergoteles
New York
– -$104K -1,220 Closed
Citadel Advisors
39
Citadel Advisors
Florida
– -$70K -826 Closed
UBS Group
40
UBS Group
Switzerland
– -$7.79K -112 -94%
CAPTRUST Financial Advisors
41
CAPTRUST Financial Advisors
North Carolina
– -$9K -106 Closed
Fidelity Investments
42
Fidelity Investments
Massachusetts
– -$1.39K -20 -69%
TRCT
43
Tower Research Capital (TRC)
New York
– -$1K -11 Closed
Wells Fargo
44
Wells Fargo
California
– +$209 +3 +150%
Royal Bank of Canada
45
Royal Bank of Canada
Ontario, Canada
– +$348 +5 New
1
2

FNCH Hedge Fund Activity: Q3 2022 in Review

43 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q3 2022, worth a combined $16.8M — down 40% from $28M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of FNCH and 4 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 9 added.

The largest buyer was SVB Wealth, opening a new position worth an estimated $587K. The largest seller was Ikarian Capital, cutting an estimated $216K.

  • 43 institutional investors held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q3 2022, down from 46 in Q2 2022.
  • Funds reported $16.8M of Finch Therapeutics Group, Inc. Common Stock stock for Q3 2022, down 40% quarter-over-quarter.
  • 4 funds opened new Finch Therapeutics Group, Inc. Common Stock positions in Q3 2022 and 7 closed out, a net change of -3 holders.
  • The largest Finch Therapeutics Group, Inc. Common Stock buyer in Q3 2022 was SVB Wealth, an estimated $587K added.
  • The largest Finch Therapeutics Group, Inc. Common Stock seller in Q3 2022 was Ikarian Capital, an estimated $216K sold.

Based on aggregated 13F filings for Q3 2022.